Results 51 to 60 of about 67,862 (241)

BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure [PDF]

Journal of Biological Chemistry, 2012
The tumor suppressor breast cancer susceptibility gene 2 (BRCA2) plays an important role in the repair of DNA damage, and loss of BRCA2 predisposes carriers to breast and ovarian cancers. Doxorubicin (DOX) remains the cornerstone of chemotherapy in such individuals.
Singh KK, Shukla PC, Quan A, Desjardins JF, Lovren F, Pan Y, Garg V, Gosal S, Garg A, Szmitko PE, Schneider MD, Parker TG, Stanford WL, Leong-Poi H, Teoh H, Al-Omran M, Verma S   +16 more
openaire   +2 more sources

Is Lactate an Oncometabolite? Evidence Supporting a Role for Lactate in the Regulation of Transcriptional Activity of Cancer-Related Genes in MCF7 Breast Cancer Cells. [PDF]

, 2019
Lactate is a ubiquitous molecule in cancer. In this exploratory study, our aim was to test the hypothesis that lactate could function as an oncometabolite by evaluating whether lactate exposure modifies the expression of oncogenes, or genes encoding ...
Brooks, George A, Julian, Colleen G, Martinez, Janel, Matarazzo, Christopher, San-Millán, Iñigo   +4 more
core   +1 more source

Assessment of PALB2 as a candidate melanoma susceptibility gene.

PLoS ONE, 2014
Partner and localizer of BRCA2 (PALB2) interacts with BRCA2 to enable double strand break repair through homologous recombination. Similar to BRCA2, germline mutations in PALB2 have been shown to predispose to Fanconi anaemia as well as pancreatic and ...
Lauren G Aoude, Mai Xu, Zhen Zhen Zhao, Michael Kovacs, Jane M Palmer, Peter Johansson, Judith Symmons, Jeffrey M Trent, Nicholas G Martin, Grant W Montgomery, Kevin M Brown, Nicholas K Hayward   +11 more
doaj   +1 more source

No evidence of BRCA2 mutations in chromosome 13q-linked Utah high-risk prostate cancer pedigrees

BMC Research Notes, 2009
Background Germline mutations in the BRCA2 gene have been suggested to account for about 5% of familial prostate cancer; mutations have been reported in 2% of early onset (i.e., ≤ 55 years) prostate cancer cases and a segregating founder mutation has ...
Allen-Brady Kristina, Farnham James M, Camp Nicola J, Karlins Eric, Ostrander Elaine A, Cannon-Albright Lisa A   +5 more
doaj   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

Novel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer Cell

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2016
Mutation of breast cancer 2, early onset (BRCA2) has been identified as a vital risk factor for esophageal cancer (EC). To date, several proteins have been reported as BRCA2-interacting proteins and are associated with multiple biological processes. This study’s aim was to identify a novel interactive protein of BRCA2 and to explore its functional ...
Hou, Xiaobin, Li, Tinghui, Ren, Zhipeng, Liu, Yang   +3 more
openaire   +3 more sources

BRCA1 and BRCA2 proteins: roles in health and disease. [PDF]

Molecular Pathology, 1998
Between 5% and 10% of all breast cancer is hereditary, with patients having a strong family history of the disease. The remaining 90-95% of cases are classed as sporadic. Within the inherited group, 80-90% of cases are the result of germline mutations affecting two recently identified genes: BRCA1 and BRCA2.
J A, Duncan, J R, Reeves, T G, Cooke
openaire   +2 more sources

Breast cancer risks associated with missense variants in breast cancer susceptibility genes

Genome Medicine, 2022
Background Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain.
Leila Dorling, Sara Carvalho, Jamie Allen, Michael T. Parsons, Cristina Fortuno, Anna González-Neira, Stephan M. Heijl, Muriel A. Adank, Thomas U. Ahearn, Irene L. Andrulis, Päivi Auvinen, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Marina Bermisheva, Natalia V. Bogdanova, Stig E. Bojesen, Manjeet K. Bolla, Michael Bremer, Ignacio Briceno, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Jenny Chang-Claude, Stephen J. Chanock, Georgia Chenevix-Trench, NBCS Collaborators, J. Margriet Collée, Kamila Czene, Joe Dennis, Thilo Dörk, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Henrik Flyger, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat García-Closas, Graham G. Giles, Gord Glendon, Pascal Guénel, Melanie Gündert, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Elaine F. Harkness, Mikael Hartman, Frans B. L. Hogervorst, Antoinette Hollestelle, Reiner Hoppe, Anthony Howell, kConFab Investigators, SGBCC Investigators, Anna Jakubowska, Audrey Jung, Elza Khusnutdinova, Sung-Won Kim, Yon-Dschun Ko, Vessela N. Kristensen, Inge M. M. Lakeman, Jingmei Li, Annika Lindblom, Maria A. Loizidou, Artitaya Lophatananon, Jan Lubiński, Craig Luccarini, Michael J. Madsen, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Dimitrios Mavroudis, Roger L. Milne, Nur Aishah Mohd Taib, Kenneth Muir, Heli Nevanlinna, William G. Newman, Jan C. Oosterwijk, Sue K. Park, Paolo Peterlongo, Paolo Radice, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Xueling Sim, Melissa C. Southey, Harald Surowy, Maija Suvanto, Ian Tomlinson, Diana Torres, Thérèse Truong, Christi J. van Asperen, Regina Waltes, Qin Wang, Xiaohong R. Yang, Paul D. P. Pharoah, Marjanka K. Schmidt, Javier Benitez, Bas Vroling, Alison M. Dunning, Soo Hwang Teo, Anders Kvist, Miguel de la Hoya, Peter Devilee, Amanda B. Spurdle, Maaike P. G. Vreeswijk, Douglas F. Easton   +108 more
doaj   +1 more source

PARP-1 regulates DNA repair factor availability. [PDF]

, 2018
PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic
Birbe, Ruth, Brand, Lucas J, Cendon-Florez, Ylenia, Chand, Saswati N., de Leeuw, Renée, Dicker, Adam, MD, PhD, Dylgjeri, Emanuela, Evans, Joseph, Feng, Felix Y, Gallagher, Peter, Gaur, Sanchaika, Gomella, Leonard G, Gordon, Nicolas, Han, Sumin, Huang, Fangjin, Kelly, William Kevin, Knudsen, Beatrice, Knudsen, Karen E, Lallas, Costas D, Leiby, Benjamin E, Mandigo, Amy C., McCann, Jennifer J, McCue, Peter, McNair, Christopher, Parsons, Theodore, Poudel Neupane, Neermala, Raj, Ganesh V, Schiewer, M J, Shafi, Ayesha A, Trabulsi, Edouard J, Visakorpi, Tapio, Zhao, Shuang G   +31 more
core   +2 more sources

A complete protein truncation test for BRCA1 and BRCA2 [PDF]

European Journal of Human Genetics, 1998
The protein truncation test (PTT) is currently the fastest method in general use for detecting previously unidentified mutations in tumor suppressor genes. Greater than three kilobases of coding sequence can be screened by one PCR reaction, one coupled in vitro transcription/translation reaction, and one lane on an SDS-PAGE gel.
openaire   +2 more sources